Histalog — Competitive Intelligence Brief

Histalog (BETAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: betazole. Area: Other.

marketed betazole Histamine H2 receptor Other Small molecule

Target snapshot

Histalog (BETAZOLE).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Histalog TARGET	BETAZOLE		marketed	betazole	Histamine H2 receptor	1982-01-01
Axid Ar	NIZATIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1988-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Tagamet	CIMETIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1977-01-01
Bentyl	dicycloverine	Forest Labs Inc	marketed	Anticholinergic	Histamine H2 receptor	1950-01-01
Rosuvastatin-ranitidine	Rosuvastatin-ranitidine	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist	HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component)
Famotidine (FAM)	Famotidine (FAM)	Bristol-Myers Squibb	marketed	H2-receptor antagonist	Histamine H2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (betazole class)

1. · 1 drug in this class